(MENAFN) The Centers for Disease Control and Prevention (CDC) has revealed that the outbreak of extensively drug-resistant bacteria associated with recalled eye drops earlier this year is persisting and has shown signs of further growth. According to the latest figures published by the CDC on Friday, there have been a total of 81 reported cases and four deaths across 18 states.
This update from the agency marks the first increase in deaths since March, when three fatalities were initially recorded. Additionally, the CDC has confirmed an additional 13 cases, although it is important to note that approximately half of these cases were detected from specimens collected before the eye drop recall in February.
The CDC explained that the delay in confirming these cases was due to the time required for testing to confirm the outbreak strain and retrospective reporting of infections. As a result, the reported cases have extended beyond the recall date, contributing to the growing numbers.
For several months, the Food and Drug Administration (FDA) has been urging the public to cease using two brands of eye drops that investigators suspect are linked to the outbreak. The brands in question are Delsam Pharma and EzriCare, and the FDA has advised individuals to discontinue their use in order to prevent further infections.
The outbreak of extensively drug-resistant bacteria associated with these eye drops is a matter of significant concern for public health officials. The continued spread of the bacteria, coupled with the reported deaths, underscores the urgent need for heightened vigilance and precautionary measures. Efforts to raise awareness about the recall and the potential risks associated with these products are crucial in preventing further infections and safeguarding public health.
As health authorities and investigators work to contain the outbreak and identify additional cases, it is essential for individuals to remain informed and follow the guidance provided by the CDC and FDA. By staying updated on the latest developments and adhering to recommended precautions, the public can contribute to mitigating the impact of this concerning situation.
MENAFN21052023000045014228ID1106283074
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.